GRFS

Q: What is the price of Grifols (GRFS) today?

The price of Grifols (GRFS) today is $ 8.84, with return of 27.29% compared to the last year. The price of Grifols (GRFS) started the year trading around $ 9.35 and today it is at $ 8.84. Follow the real-time price chart, the historical price of Grifols (GRFS) and international markets.

Q: When does Grifols (GRFS) pay dividends?

Grifols (GRFS) did not distribute dividends in the last year.

Q: Is Grifols (GRFS) worth it?

Currently, Grifols (GRFS) is priced at $ 8.84, with a P/E of 15.43%, representing a deviation of 2,555% from its historical average P/E. In the last year, the stock showed a variation of 27.29 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 1.85%. The total shareholder return was 27.29%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy Grifols (GRFS) stock?

Investing in stocks of Grifols (GRFS) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of Grifols (GRFS) yield today?

The yield of Grifols (GRFS) was -2.10% in the last month, 27.29% in the last year and -53.35% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.17 in dividends, with a Dividend Yield of 1.85%.If you wanted to buy 100 stocks of Grifols (GRFS) today, the total investment would be $ 884.00, based on the current price of $ 8.84.If past performance were to repeat, the return on your investment would be:In 1 year: $ 1,125.24In 5 years: $ 412.39In 10 years: $ 598.73It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Grifols S.A.

Price

$ 8.84

return (12m)

27.29%

p/e

15.43

p/bv

0.72

DIVIDEND YIELD

1.85%

price GRFS

GRFS

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return of GRFS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-2.10%

3 months

-9.33%

1 year

27.29%

2 years

27.84%

5 years

-53.35%

10 years

-32.27%

Fundamentals GRFS

review the fundamentals of Grifols shares

P/E

15.43

Sector: -3.66 Industry: -3.66

P/SALES RATIO (PSR)

0.76

Sector: -3.63 Industry: -3.63

P/BV

0.72

Sector: 2.08 Industry: 2.08

DIVIDEND YIELD (DY)

1.85%

Sector: - Industry: -

ROA

1.78%

Sector: -63.97% Industry: -63.97%

ROE

4.67%

Sector: -66.68% Industry: -66.68%

ROIC

5.55%

Sector: -1,128.96% Industry: -1,128.96%

NET MARGIN

4.91%

Sector: -41.05% Industry: -41.05%

GROSS MARGIN

39.48%

Sector: 39.22% Industry: 39.22%

OPERATING MARGIN

18.64%

Sector: -40.98% Industry: -40.98%

P/EBITDA

3.32

Sector: -3.63 Industry: -3.63

P/EBIT

4.12

Sector: -3.76 Industry: -3.76

P/ASSET

0.27

Sector: 1.47 Industry: 1.47

BVPS

13.01

Sector: 1.77 Industry: 1.77

EPS

0.61

Sector: -2.03 Industry: -2.03

EQUITY RATIO

0.38

Sector: 0.41 Industry: 0.41

CAGR REVENUE 5 YEARS

22.63%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

5.29%

Sector: - Industry: -

FAIR VALUE OF Grifols ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

$ 8.84

Fair Value

$ 0.00

Upside Return potential.

51.16%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals GRFS

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	19.59	6.21	31.69%	2.51%	$ 492.17 B	27.26%
PFE	14.74	1.56	10.56%	6.75%	$ 144.85 B	15.65%
ABBV	169.26	-155.52	-91.88%	2.87%	$ 404.20 B	4.00%
NVO	16.95	9.78	57.70%	2.87%	$ 261.35 B	32.78%
MRK	14.51	0.00	0.00%	2.97%	$ 276.10 B	29.63%
AZN	31.24	6.39	20.45%	1.65%	$ 293.60 B	16.17%
BMY	18.61	6.04	32.47%	4.49%	$ 112.40 B	12.57%
GILD	18.56	7.02	37.80%	2.61%	$ 150.53 B	27.88%
ZTS	21.25	10.44	49.11%	1.57%	$ 56.34 B	28.21%
REGN	18.10	2.68	14.79%	0.44%	$ 82.84 B	32.13%
HALO	14.24	16.83	118.17%	0.00%	$ 8.48 B	47.91%
AMGN	25.05	18.24	72.82%	2.92%	$ 175.44 B	19.47%
MCK	25.09	-175.07	-697.75%	0.38%	$ 101.19 B	1.04%
VRTX	32.31	6.86	21.22%	0.00%	$ 118.75 B	31.35%
CAH	30.01	-17.53	-58.40%	1.01%	$ 47.86 B	0.68%
ADMA	20.48	9.95	48.57%	0.00%	$ 4.29 B	42.87%
BIIB	17.15	1.51	8.83%	0.00%	$ 27.58 B	15.98%

Stock vs Index Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

GRFS Historical Dividends

current DY: 1.85%

5-year average DY: 1.16%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividend	08/12/2025	08/20/2025	0,17340000
Dividend	06/04/2021	06/14/2021	0,43850000
Dividend	11/02/2020	11/09/2020	0,20140000
Dividend	12/03/2019	12/11/2019	0,22190000
Dividend	06/10/2019	06/18/2019	0,16420000
Dividend	12/03/2018	12/11/2018	0,22780000
Dividend	06/04/2018	06/12/2018	0,25100000
Dividend	12/04/2017	12/12/2017	0,21270000
Dividend	06/01/2017	06/08/2017	0,16330000
Dividend	12/07/2016	12/14/2016	0,19340000
Dividend	06/06/2016	06/15/2016	0,16190000
Dividend	12/14/2015	12/17/2015	0,19220000
Dividend	06/10/2015	06/15/2015	0,16560000
Dividend	12/08/2014	12/12/2014	0,15450000
Dividend	06/09/2014	06/13/2014	0,14350000
Dividend	06/07/2013	06/13/2013	0,13040000
Dividend	05/28/2013	06/05/2013	0,00650000

ABOUT THE COMPANY Grifols

Grifols S.A.

Average user rating I10

4.0 (2 people)

United States

39 years

Founded: 1987

2011

Time since IPO - 15 years

23.655

Employees

The Company Grifols S.A. (United States), is listed on Nasdaq with a market value of $ 6.38 Billions, having an equity of $ 8.86 Billions.

With a total of 23.655 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 8.43 Billions, which generated a profit in the amount of $ 413.63 Millions.

As for its main indicators, the Company has a P/E ratio of 15.43, a P/BV ratio of 0.72 and in the last 12 months the dividend yield of GRFS was at 1.85%.

The Company is traded internationally through the ticker GRFS.

Market cap

$ 6.38 Billions

Net worth

$ 8.86 Billions

US$ 8,859,110,000.00

Assets

$ 23.30 Billions

US$ 23,302,540,000.00

Total Shares Outstanding

681.00 Millions

681,000,000

Average Daily Trading Volume

$ 613.19 Thousand

US$ 613,192.40

Sector

Health Care

Industry

Biotechnology

GRFS

GRFS revenue and profits

Financial Results GRFS

DRAG THE FRAME TO SEE MORE DATA

GRFS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 823.98 41,82% (12M)

P/E

25.09

0.38%

ROE

-697.75%

P/BV

-175.07

CAH - Cardinal Health

$ 208.26 69,09% (12M)

P/E

30.01

1.01%

ROE

-58.40%

P/BV

-17.53

JNJ - Johnson & Johnson

$ 213.65 52,86% (12M)

P/E

19.59

2.51%

ROE

31.69%

P/BV

6.21

MRK - Merck & Co.

$ 108.26 12,23% (12M)

P/E

14.51

2.97%

ROE

0.00%

P/BV

0.00

PFE - Pfizer

$ 25.15 3,56% (12M)

P/E

14.74

6.75%

ROE

10.56%

P/BV

1.56

ABBV - AbbVie

$ 220.75 34,36% (12M)

P/E

169.26

2.87%

ROE

-91.88%

P/BV

-155.52

AZN - AstraZeneca

$ 94.51 46,96% (12M)

P/E

31.24

1.65%

ROE

20.45%

P/BV

6.39

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 823.98 41,82% (12 M)

P/L

25.09

0.38%

ROE

-697.75%

P/VP

-175.07

CAH - Cardinal Health

$ 208.26 69,09% (12 M)

P/L

30.01

1.01%

ROE

-58.40%

P/VP

-17.53

JNJ - Johnson & Johnson

$ 213.65 52,86% (12 M)

P/L

19.59

2.51%

ROE

31.69%

P/VP

6.21

MRK - Merck & Co.

$ 108.26 12,23% (12 M)

P/L

14.51

2.97%

ROE

0.00%

P/VP

0.00

PFE - Pfizer

$ 25.15 3,56% (12 M)

P/L

14.74

6.75%

ROE

10.56%

P/VP

1.56

ABBV - AbbVie

$ 220.75 34,36% (12 M)

P/L

169.26

2.87%

ROE

-91.88%

P/VP

-155.52

AZN - AstraZeneca

$ 94.51 46,96% (12 M)

P/L

31.24

1.65%

ROE

20.45%

P/VP

6.39

Frequently Asked Questions

What is the price of Grifols (GRFS) today?

The price of Grifols (GRFS) today is $ 8.84, with return of 27.29% compared to the last year. The price of Grifols (GRFS) started the year trading around $ 9.35 and today it is at $ 8.84. Follow the real-time price chart, the historical price of Grifols (GRFS) and international markets.

When does Grifols (GRFS) pay dividends?

Grifols (GRFS) did not distribute dividends in the last year.

Is Grifols (GRFS) worth it?

Currently, Grifols (GRFS) is priced at $ 8.84, with a P/E of 15.43%, representing a deviation of 2,555% from its historical average P/E. In the last year, the stock showed a variation of 27.29 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 1.85%. The total shareholder return was 27.29%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Grifols (GRFS) stock?

Investing in stocks of Grifols (GRFS) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Grifols (GRFS) yield today?

The yield of Grifols (GRFS) was -2.10% in the last month, 27.29% in the last year and -53.35% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.17 in dividends, with a Dividend Yield of 1.85%.

If you wanted to buy 100 stocks of Grifols (GRFS) today, the total investment would be $ 884.00, based on the current price of $ 8.84.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 1,125.24
In 5 years: $ 412.39
In 10 years: $ 598.73

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

GRFS

Grifols S.A.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return of GRFS

review the fundamentals of Grifols shares

P/E

P/SALES RATIO (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

P/EBITDA

P/EBIT

P/ASSET

BVPS

EPS

EQUITY RATIO

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 1.85%

5-year average DY: 1.16%

type

Ex - Dividend Date

payment date

value

ABOUT THE COMPANY Grifols

Grifols S.A.

United States

39 years

2011

23.655

PROFIT X PRICE GRFS

Financial Results GRFS

GRFS cash flow

asset growth - GRFS

GRFS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

ABBV - AbbVie

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

ABBV - AbbVie

AZN - AstraZeneca

Frequently Asked Questions